Search

Displaying results 5151 - 5160 of 8974 in total
  1. Drug

    Ibrigampar

    go.drugbank.com/drugs/DB05490
    Investigational

    AMG-131 (T131), an orally-administered therapy, is expected to lower blood glucose in type II diabetic patients by improving the body’s ability to respond to insulin. … T131 is a selective modulator of PPARg (peroxisome proliferator activated receptor gamma), a receptor involved in regulating the body’s ability to respond to insulin.

  2. Drug

    Elacridar

    go.drugbank.com/drugs/DB04881
    Investigational

    Development is assumed to have been discontinued. … In many cases, the appearance of multidrug resistance in cancer is due to a change in expression of protein inhibitors. As of August 2007 elacridar was not listed on GSK's product pipeline.

  3. Drug

    mRNA-3705

    go.drugbank.com/drugs/DB17668
    Investigational

    Developed by Moderna TX Inc., it is being investigated for the treatment of methylmalonic academia.[A258843]

  4. Drug

    SQ-109

    go.drugbank.com/drugs/DB05186
    Investigational

    SQ-109 is an orally active, small molecule antibiotic for treatment of pulmonary TB. … Currently in Phase I clinical trials, SQ-109 could replace one or more drugs in the current first-line TB drug regimen, simplify therapy, and shorten the TB treatment regimen.

  5. Drug

    Fenthion

    go.drugbank.com/drugs/DB11412
    ExperimentalVet approved

    Fenthion is listed as a restricted use compound by the United States Environmental Protection Agency due to its potential to cause cholinesterase inhibition in humans and animals. … Its mode of action is explained by cholinesterase enzyme inhibition, which is similar to other organophosphates.

    Categories: Compounds used in a research, industrial, or household settingSynonyms: O,O-Dimethyl O-4-methylthio-m-tolyl phosphorothioate, O,O-Dimethyl O-[3-methyl-4-(methylsulfanyl)phenyl] thiophosphate
  6. Drug

    Folitixorin calcium

    go.drugbank.com/drugs/DB05308
    Investigational

    ANX-510 (CoFactor) is a folate-based biomodulator drug being developed to enhance the activity and reduce associated toxicity of the widely used cancer chemotherapy, 5-fluorouracil (5-FU).

  7. Drug

    SPL84-23-1

    go.drugbank.com/drugs/DB18575
    Experimental

    SPL84-23-1 is a sodium salt of 19-bp single-stranded RNA uniformly modified 2'-O-(2-methoxyethyl) phosphorothioate Antisense Oligonucleotide (ASO) consisting of 19 nucleotide residues with the sequence

  8. Target

    Immunoglobulin heavy constant alpha 2

    go.drugbank.com/bio_entities/BE0004610
    TargetHumans

    for a particular antigen (PubMed:17576170, PubMed:20176268). … The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation

    Synonyms: Ig alpha-2 chain C region BUT
  9. Target

    Immunoglobulin heavy constant alpha 1

    go.drugbank.com/bio_entities/BE0005097
    TargetHumans

    for a particular antigen (PubMed:17576170, PubMed:20176268). … The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation

    Synonyms: Ig alpha-1 chain C region BUR
  10. Drug

    Progabide

    go.drugbank.com/drugs/DB00837
    Experimental

    It has agonistic activity for both the GABAA and GABAB receptors. … In clinical trials, progabide has been investigated for Parkinson's disease, schizophrenia, clinical depression and anxiety disorder; its therapeutic effectiveness in these conditions is not fully elucidated